Roche, Genentech, Recursion Launch Up-to-$12B AI Drug Discov

Roche and its Genentech subsidiary have committed up to $12 billion to Recursion in return for using its Recursion Operating System (OS) to advance therapies in 40 programs that include “key areas” of neuroscience and an undisclosed oncology indication.

Related Keywords

Chris Gibson , Irit Rappley , Tim Ahfeldt , Bristol Myers Squibb , Glenn Morrison , James Sabry , Genentech , Icahn School Of Medicine At Mount Sinai , Softbank , Translational Research , Clinical Development , Recursion Operating System , Recursion Data Universe , Neurofibromatosis Type , Icahn School , Mount Sinai , Scientific Director , Vice President , Bloomberg News , Global Head , Pharma Partnering ,